


Improving Anaphylaxis Outcomes: Approaches for Enhancing Access to Epinephrine

Hybrid Meeting | Duke in DC Office
9:00 AM – 4:30 PM ET, Dec 16, 2025

Speaker Biographies



Alice Hoyt, MD, is board-certified in allergy and immunology, internal medicine, and pediatrics and leads the Hoyt Institute of Food Allergy in New Orleans, Louisiana. Before starting her practice in Louisiana, she helped launch the Cleveland Clinic Food Allergy Center of Excellence. She teaches parents through her Food Allergy and Your Kiddo podcast and she trains other doctors and clinicians on food allergies through the Food Allergy Pediatric Hub. To reach schools, Dr. Hoyt leads the non-profit organization Code Ana, which equips schools for medical emergencies like anaphylaxis. Dr. Hoyt has prescribed hundreds of stock epinephrine devices to schools and other entities and has helped train thousands of individuals on the recognition and management of anaphylaxis.

***COI:** Dr. Hoyt is a volunteer board member of the 501c3 The Teal Schoolhouse, whose mission involves equipping schools and other entities be prepared for medical emergencies like anaphylaxis. She is a consultant for Kaleo, the maker of Auvi-Q. The Teal Schoolhouse received grant funding from The Peanut Board to help early childcare centers be prepared for anaphylaxis, with funds in part being used to provide centers with epinephrine auto-injectors and appropriate training.*



Brian Canter, PhD, is an Assistant Research Director on the Biomedical Innovation team working on policy solutions to improve development, regulatory review, and evidence generation for broadening access and availability to medical products. He manages one of the Biomedical Innovation team's cooperative agreements with the U.S. Food and Drug Administration (FDA). Brian's portfolio of work spans several key areas within the biomedical innovation space. As the lead researcher on regulatory considerations to enable greater competition for biologics, he has evaluated the value of the interchangeability designation and derived strategies to foster future biosimilar development for cell and gene therapies. Supporting the Institute's thought leadership to modernize clinical trials, Brian guides the policy work for the Coalition for Advancing Clinical Trials at the Point of Care. Brian has also managed several projects within the Institute's regulatory science work, including public meetings convened with FDA to advance clinical trial innovation and premarket safety analytics. In addition to biomedical innovation, Brian has done extensive work within the Institute's 21st Century Public Health and Population Health portfolio. He oversaw a project focused on addressing the burden of respiratory viruses through reduction of disease transmission. During the COVID-19 pandemic, Brian led the Institute's work to maximize adoption of therapeutics, with a focus on Test-to-Treat pathways. Prior to joining Duke-Margolis, Brian completed a PhD in Biomedical Sciences with a focus in Biomedical Engineering from Rutgers University. His thesis research focused on utilizing radiation therapy

systemically to treat metastatic breast cancer that spread to bone. Brian also graduated with a Bachelor of Science in Biomedical Engineering from Tufts University.

COI: *Dr. Canter declares that he has no conflicts of interest related to this public workshop. He has no personal or financial relationships that could influence his participation.*



Brian Vickery, MD, is Professor of Pediatrics, Marcus Professor of Pediatric Immunology and Chief of the Division of Allergy/Immunology at Emory University and Children’s Healthcare of Atlanta. He is a nationally prominent clinician-scientist focused on improving outcomes for children with allergic disease through the development and implementation of interventions that effectively address unmet medical needs. Dr. Vickery has a 15+ year track record of sustained extramural funding, national service, mentorship, and scholarship in food allergy, leading to over 125 publications in leading journals, yielding a Web of Science h-index of 43. He received his undergraduate degree at the University of Georgia

followed by his MD at the Medical College of Georgia. He then completed pediatric residency and chief residency at New York-Presbyterian Hospital/Cornell and fellowship at Yale University School of Medicine.



Carla Davis, MD, is Professor of Pediatrics and Chair of the Department of Pediatrics and Child Health at Howard University College of Medicine. She received her BS in Chemical Engineering from Howard University and her MD from Duke University. She completed her Allergy/Immunology Fellowship at Baylor College of Medicine (BCM), staying on as a faculty member and rising to be the Chief of the Immunology, Allergy, and Retrovirology Division in the BCM Department of Pediatrics. She is the Founder and was the Director of the NIH funded Texas Children’s Hospital Food Allergy Program from 2015-2024. She focuses on improving the quality of life for children with allergic and immunologic diseases, most specifically food allergy and asthma, and has participated as a site

principal investigator in multiple NIH-funded clinical trials. She has over 135 publications and has expertise in translational research studies for assessment of clinical tolerance to food and diagnostic biomarkers. She leads community initiatives to address food insecurity in underserved populations. She is the President-Elect of the American Academy of Allergy, Asthma and Immunology, and will serve as President in 2026. She is passionate about the elimination of health disparities and giving compassionate care to her patients and families.

COI: *Dr. Davis has a research contract with Novartis and a speaking contract with Genentech and Takeda.*



Charity Luiskutty, PA-C, is a Physician Assistant and currently practices at Children’s Specialty Group Allergy and Immunology at the Children’s Hospital of the King’s Daughters in Norfolk, Virginia with a special interest in food allergy and treatments. She is a FAACT Advocate and has been involved in their Leadership, Teen, and Global Food Industry Summits as well as a guest on their Roundtable Podcast. Charity is the current president of the Coastal Food Allergy Support group in Southeast Virginia where she has been a part since 2011 and served previously as their Education and Outreach Coordinator. She is also the wife of a food allergic adult and mother of 3 food allergic children.

***COI:** Charity declares that she has no conflicts of interest related to this public workshop. She has no personal or financial relationships that could influence her participation.*



Christopher Warren, MD, PhD, is a doctorally-trained epidemiologist, health behavior researcher and prevention scientist who has conducted research into the public health burden of food allergy and other atopic disease since 2011. He received his doctorate in 2019 from the University of Southern California Keck School of Medicine's Department of Population and Public Health Sciences and completed a postdoctoral fellowship at the Sean N. Parker Center for Allergy and Asthma Research at Stanford University in 2021. As Assistant Professor of Preventive Medicine and Director of Population Health at

Northwestern University's Center for Food Allergy and Asthma Research (CFAAR) the overarching focus of Dr. Warren's research is to characterize and ameliorate the burden of food allergy via large-scale epidemiological studies and behavioral interventions.

***COI:** Dr. Warren receives research support provided to his institution from NIAID/NIH, Food Allergy Research and Education, Genentech Inc, Abbott Nutrition, and the US Centers for Disease Control and Prevention. However, he has not received payment or other non-monetary support from any company involved in the manufacture or sale of epinephrine products. He reports no conflicts of interest with respect to ongoing efforts to enhance access to epinephrine and improve anaphylaxis outcomes.*




Hemant Sharma, MD, MHS, is Chief of the Division of Allergy and Immunology at Children’s National Hospital in Washington, D.C. He is a Professor of Pediatrics at George Washington University School of Medicine.

Dr. Sharma is the founding Director of the Food Allergy Program at Children’s. His research and advocacy focus on health equity and the psychosocial impact of food allergy. For over ten years, Dr. Sharma wrote the “Ask the Expert” column in *Allergic Living* magazine, and he also served on the Board of Advisors

for *Parents* magazine. Due to his efforts on behalf of the patient community, he received the FARE Food Allergy Vision Award. Dr. Sharma is a Fellow of the American Academy of Allergy, Asthma and Immunology, having served as Chair of the Integrative Medicine Committee and co-chair of the Clinician Wellness Workgroup.

***COI:** Dr. Hemant Sharma receives grant funding from NIAID and has consulted with Genentech/Novartis for an unbranded educational campaign.*



Hugh Sampson, MD, is the Kurt Hirschhorn Professor of Pediatrics at the Icahn School of Medicine. His research has been continuously funded by the NIH, including the initial Principal Investigator for the *Consortium for Food Allergy Research*, and focused on food allergic disorders, including work on the pathogenesis of food-induced anaphylaxis, characterization of allergenic food proteins and their processing by the immune system, development of novel diagnostic tests, and mechanisms of immunotherapeutic strategies for treating food allergies, including basic studies and clinical trials in immunotherapy and biologics. He has authored/co-authored over 600 original articles and 90 book chapters, and co-edited 5 books, primarily on clinical and immunopathogenic aspects of food allergic disorders. He chaired working groups that produced standardized criteria for diagnosing anaphylaxis and conducting double-blind placebo-controlled oral food challenges (*Practall Guidelines*) and was a member of the NIH – NIAID Working Groups formulating *Guidelines on Food Allergy*. Dr. Sampson was elected to membership in the National Academy of Medicine in 2003 for his research accomplishments. He has mentored over 50 postdoctoral fellows, many of whom are now leaders in the field, and served in leadership roles in multiple organizations including the Presidency of the *American Academy of Allergy, Asthma, and Immunology*.

COI: Dr. Hugh Sampson reports grants from the Immune Tolerance Network, NIAID/NIH, and the Food Allergy Research & Education (FARE) foundation, personal fees from N-Fold LLC, DBV Technologies, Alpina Biotech AG, RAPT Therapeutics and FARE, stock/stock options from N-Fold LLC and DBV Technologies, and royalties from Wiley and Elsevier.



Julie Wang, MD, is Professor of Pediatrics in the Division of Allergy and Immunology at the Icahn School of Medicine at Mount Sinai. Dr. Wang's research focuses on clinical trials developing new treatments for food allergies as well as studies aimed at better understanding how patients and their families manage food allergies and anaphylaxis in schools and other community settings. As a member of the Joint Task Force on Practice Parameters and immediate-past Chair of the Executive Committee of the Section on Allergy and Immunology of the American Academy of Pediatrics, Dr. Wang has co-authored pediatric and allergy guidelines on food allergy and anaphylaxis. She is also a member of the board of directors of the American Board of Allergy and Immunology and Chair of the American Academy of Allergy Asthma and Immunology Annual Meeting Programming Committee. She has published over 170 articles in scientific journals and has authored over 20 book chapters in major pediatric and allergy textbooks. Dr. Wang is on the editorial board for the *Journal of Allergy and Clinical Immunology* and *Journal of Allergy and Clinical Immunology: In Practice*. She is co-program director for the Mount Sinai Allergy and Immunology Fellowship Training Program.

COI: Dr. Wang reports clinical trials support (money to institution) from NIH, DBV Technologies, and Siolta; She has received consulting fees from kaleo and Aquestive.



Karen Minerve Murry, MD, is Acting Director of the Office of Nonprescription Drugs (ONPD) at FDA. In her role, she works on multiple innovative and strategic initiatives with the goal of improving self-care for Americans through expanded availability of safe, effective, and affordable nonprescription medicines. She is an endocrinologist who received her medical degree from the University of Texas Southwestern Medical School, and her postgraduate medical training and fellowship at Walter Reed Army Medical Center. After Army service as Chief of Endocrinology at Eisenhower Army Medical Center, she began her FDA career in

the Division of Metabolism and Endocrinology Products, where she served as Diabetes Team Leader. She has served as Deputy Director for Nonprescription Drugs since 2014. She has served as clinical lead on multiple landmark projects, including the rule for an Additional Condition for Nonprescription Use, which harnesses the power of technology to make possible wider nonprescription drug availability; the Naloxone Model Drug Facts Label project that made possible the first nonprescription naloxone product, which was followed by a 30% decrease in opioid overdose deaths; and multiple areas of implementation of the monograph reform provisions of the CARES Act.

COI: *Dr. Murry declares that she has no conflicts of interest related to this public workshop. She has no personal or financial relationships that could influence her participation.*



Kelly Cleary, MD, is the Medical Director and Vice President of Health and Education for FARE. She oversees FARE's national education efforts and maintains a variety of programs, resources, and relationships for the food allergic, their families, and caregivers. Previously, Kelly was the Medical Director of Psychopharmacology for PM Behavioral Health, where she was responsible for the oversight of medication management and operations for the behavioral health service. Kelly also co-founded UrgiKids, a pediatric urgent care in Naperville, Illinois, which was subsequently acquired by PM Pediatrics. A graduate of Albert Einstein College of Medicine, Kelly completed her Pediatrics residency at New York Presbyterian Cornell, and finished her Pediatric Emergency Medicine fellowship at NYU-Bellevue. She is currently pursuing

a master's in public health degree at Johns Hopkins Bloomberg School of Public Health

COI: *Dr. Cleary does not have any conflicts of interest to report other than working at FARE.*



Kelly Stone, MD, PhD, is a board-certified pediatric allergist/immunologist who serves as a supervisory physician and Associate Director for Therapeutic Review in the CDER Division of Pulmonology, Allergy, and Critical Care. In this role, he leads regulatory review efforts for products to treat allergic/immunologic diseases and asthma. Kelly previously served as Deputy Chief of the NIAID Laboratory of Allergic Diseases, where he was also a senior physician and clinical investigator, and as Director of the NIH Clinical Center Allergy and Immunology Fellowship Program; he has also served on the faculty at Children's Hospital Boston and Children's National Medical Center. Kelly has served in national leadership roles in allergy/immunology including serving on the board of directors of the American

Academy of Allergy, Asthma, and Immunology, as chair of the Accreditation Council for Graduate Medical Education Allergy/Immunology Review Committee, the American Board of Allergy and

Immunology, and on the FDA Pulmonary-Allergy Drugs Advisory Committee. He was the recipient of the NIH Director's Ruth Kirschstein Mentoring Award, the NIH Clinical Center Distinguished Clinical Teacher Award, the FDA CDER Excellence in Mentoring Award, as well as NIH and FDA awards for scientific, regulatory, and administrative accomplishments.

COI: *Dr. Stone declares that he has no conflicts of interest related to this public workshop. He has no personal or financial relationships that could influence his participation.*



Linda Jones Herbert, PhD, is an Associate Professor of Psychology & Behavioral Health at Children's National Hospital and an Associate Professor of Pediatrics at the George Washington University School of Medicine in Washington, DC. Dr. Herbert is the Director of Psychology Research and Clinical Services for the Division of Allergy and Immunology at Children's National. Dr. Herbert is an NIH-funded clinical researcher whose research interests include pediatric allergic diseases and the development of behavioral interventions for patients with food allergy and their caregivers. Currently Dr. Herbert is the Principal Investigator for an NIAID-funded clinical trial of a behavioral intervention for early adolescents with food allergy to support their growing food allergy autonomy. Dr. Herbert presents her research at pediatric psychology and allergy/immunology conferences and food allergy patient advocacy organization conferences, and she is a prior recipient of the Heritage Lectureship award from the American Academy of Allergy, Asthma and Immunology.

COI: *Dr. Herbert reports research funding from NIAID and Leidos. In 2025 she received a speaker honorarium from Food Allergy Canada.*



Marcus Shaker, MD, is a Professor of Pediatrics and of Medicine at the Dartmouth Geisel School of Medicine, and a member of the AAAAI Board of Directors and AAAAI/ACAAI Joint Task Force on Practice Parameters. Dr. Shaker is also an Associate Editor of *Annals of Allergy, Asthma, and Immunology* and an Editorial Board member of *The Journal of Allergy and Clinical Immunology In Practice* and *The Journal of Food Allergy*. Dr. Shaker's research interests center around optimizing value-based care in Allergy and Clinical Immunology. He has published over 250 articles and guidelines. Views expressed are his own.

COI: *Dr. Shaker is a member of the Joint Task Force on Practice Parameters, serves on the editorial board of *The Journal of Allergy and Clinical Immunology In Practice*, is an associate editor of *Annals of Allergy, Asthma, and Immunology*, and serves on the Board of Directors of the American Academy of Allergy, Asthma, and Immunology (views expressed are his own); serves as a strategic medical partner for allergy immunology for Social Theory.*



Mary Thanh Hai, MD, is an internist/endocrinologist receiving her medical degree from Georgetown University. She started her career at the FDA in 1998 as a medical officer in the Division of Metabolism and Endocrine Products (DMEP). Over the years she held several leadership positions including Director of DMEP from 2006-2012, then Office Deputy overseeing three review divisions from 2013-2020. She joined the Office of New Drugs Immediate Office in 2020 as Deputy Director for Clinical, and in her current role as Director for the OND, she provides regulatory and scientific oversight of prescription and non-prescription drugs and therapeutic biologics while collaborating with other Offices and Centers at the FDA. Over her 26+ years at the Food and Drug Administration (FDA), Dr. Thanh Hai has served on several internal and external committees on a wide range of issues, including serving as rapporteur for an ICH E19 expert work group to promote selective safety data collection in late-stage pre-market and post-marketing studies and leading the Prescription Drug User Fee Act (PDUFA) reauthorization negotiations for premarket activities.

COI: *Dr. Thanh Hai will provide her conflict-of-interest statement in her opening remarks.*



Matthew Greenhawt, MD, MBA, MSc, became the Chief Medical Officer of AAFA in 2025. Dr. Greenhawt is board certified in pediatrics and allergy/immunology and brings years of clinical and research experience in asthma and allergic conditions. Prior to joining AAFA, he served as a professor of pediatrics at Children's Hospital Colorado and the University of Colorado School of Medicine, where he had served as director of the Food Challenge and Research Unit. He previously co-founded and co-directed the Pediatric Combined Eosinophilic Esophagitis Clinic and served as Research Director of the University of Michigan Food Allergy Center. Dr. Greenhawt is a member of multiple committees within

the American Academy of Allergy, Asthma & Immunology (AAAAI) and European Academy of Allergy and Clinical Immunology (EAACI). He is a past chair of the American College of Allergy, Asthma & Immunology (ACAAI) Food Allergy Committee and is finishing a 10-year term on the AAAAI/ACAAI Joint Taskforce on Allergy Practice Parameters. He has over 350 peer-reviewed publications that help elevate the standard of care in allergy/immunology.

COI: *Dr. Greenhawt is employed by the Asthma and Allergy Foundation of America, is a consultant for Aquestive; is a speaker for ARS and Genentech; serves as an advisory board member for Aquestive, ALK-Abello, Allergy Therapeutics, AstraZeneca, Bryn Pharma, DBV Technologies, Novartis, Nutricia, and Protia; is an unpaid member of the scientific advisory council for the National Peanut Board, the medical advisory board of the International Food Protein Induced Enterocolitis Syndrome Association; serves as a member of the Brighton Collaboration Criteria Vaccine Anaphylaxis 2.0 working group; is the senior associate editor for the Annals of Allergy, Asthma, and Immunology; and is an emeritus member of the Joint Task Force on Allergy Practice Parameters.*



Michael Pistiner, MD, MMSc, is a pediatric allergist/immunologist and the Director of Food Allergy Advocacy, Education & Prevention at the Mass General Brigham for Children Food Allergy Center. He also serves as an Assistant Professor of Pediatrics at Harvard Medical School. Dr. Pistiner's work focuses on food allergy and anaphylaxis management in infants and toddlers, clinician and community education, school food allergy management, and supporting the quality of life of individuals with food allergies. He is also the father of a 22-year-old with food allergies, which further informs and motivates his work. Dr. Pistiner is an active fellow of the American Academy of Pediatrics and a member of both the American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma & Immunology (ACAAI), where he serves as Chair of the ACAAI Anaphylaxis Committee. He also holds advisory roles with the Asthma and Allergy Foundation of America (AAFA), the Allergy & Asthma Network (AAN), and Food Allergy Research & Education (FARE), supporting national advocacy and patient-centered policy initiatives. He has been deeply involved in policy and advocacy efforts across multiple settings, including schools, with a focus on strengthening food allergy and anaphylaxis management and advancing education to improve safety and quality of life.

COI: *Dr. Pistiner has the following financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in this training: Research support from Egg Nutrition Center and kaleo; Consultant/Advisor for AAFA National, AAN, FARE; Program support for DBV Technologies, National Peanut Board, ARS, Aquestive, Stallergenes Greer, AAN, AAFA Advisory Board: Novartis, Bryn, kaleo, Anjo, Food Graph; Co-Founder and Content Creator for Allergy Home and Allergy Certified Training.*



Miya Paterniti, MD, is a board-certified allergist and clinical immunologist and a clinical team leader in the Division of Pulmonology, Allergy and Critical Care. She is also an Assistant Professor at The Johns Hopkins School of Medicine and a practicing allergist. She joined FDA in 2012. She has been involved in reviewing epinephrine products since 2018.

COI: *Dr. Paterniti declares that she has no conflicts of interest related to this public workshop. She has no personal or financial relationships that could influence her participation.*



Nissa Shaffi, MS, is the Director of Advocacy for the Allergy & Asthma Network. As Director of Advocacy, Nissa is the strategic architect of Allergy & Asthma Network's federal and state policy and advocacy initiatives, leveraging her expertise across federal programs, consumer protections, health systems, and patient advocacy. Prior to the Network, Nissa served as Associate Director of Public Policy at the Alliance of Community Health Plans, where she led policy efforts on Medicaid, Dual Eligibles, and the Commercial Market. In her previous role as Associate Director of Health Policy at the National Consumers League, she led national campaigns on medication adherence, vaccine confidence, and anti-counterfeit drugs. She also frequently testified before the U.S. Food and Drug

Administration (FDA) and U.S. Centers for Disease Control and Prevention (CDC) vaccine advisory committees to advocate for safe and expedited approval of vaccines for vulnerable populations. Nissa's commitment to dismantling barriers to access in healthcare and fostering patient empowerment were catalyzed by her direct experience in emergency services at Inova Health System. A native Virginian, Nissa holds a bachelor's degree in health administration and policy and a master's degree in health policy from George Mason University.

COI: *Nissa is employed by an organization that receives funding from pharmaceutical companies.*



Paul Greenberger, MD, has research interests that include drug allergy, idiopathic anaphylaxis, allergic bronchopulmonary aspergillosis, moderate to severe asthma and its particular endotypes and phenotypes, and the use of anti-TSLP with or without allergen immunotherapy in treatment of cat allergy. He graduated from the Indiana University School of Medicine and interned at the Methodist Hospital in Indianapolis. He completed my internal medicine residency at the Jewish Hospital of St. Louis. His fellowship in allergy and immunology was at Northwestern University, where he served as faculty for 45 years until transitioning to Emeritus status in 2022. He has published over 300 original manuscripts and 112 reviews/book chapters and is co-editor and an author of Patterson's Allergic Diseases, now in its 8th edition. It has been his pleasure to have served as President of the American Academy of Allergy Asthma and Immunology and on the board of the World Allergy Organization. Since 2013, he has been a consultant to and member of advisory committees of the Food and Drug Administration. Lastly, he takes great pride in participating in the post-graduate education of 175 allergy-immunology fellows at Northwestern University Feinberg School of Medicine since 1978.

COI: *Dr. Greenberger consults for Allergy Therapeutics (UK), and receives Wolters Kluwer-book royalty and royalties from Up-To-Date as a reviewer. He also participated in FDA-advisory committees*



Ruchi Gupta, MD, MPH, is a Professor of Pediatrics and Medicine at Northwestern University Feinberg School of Medicine, a Clinical Attending at Ann & Robert H. Lurie Children's Hospital of Chicago, and the founding director of the Center for Food Allergy & Asthma Research (CFAAR). A trailblazer in the field, Dr. Gupta has dedicated more than 20 years to pioneering research, creating solutions for families, and driving national health policy. With over 300 peer-reviewed publications to her name, her groundbreaking work has been spotlighted by major platforms including *Netflix*, *The New York Times*, and *PBS* solidifying her as one of the most trusted voices in food allergy care today.

COI: *Dr. Gupta receives research support from the National Institutes of Health (NIH), Food Allergy Research & Education (FARE), Sunshine Charitable Foundation, Genentech, Novartis, and Abbott Laboratories. She serves as a medical consultant/advisor for Food Allergy Research & Education (FARE), Genentech, Novartis, OWYN, Kaléo, Bryn Pharma, Kenvue, ARS Pharmaceuticals, Oracle Life*

Sciences, and Alpina Biotechnology. Dr. Gupta has ownership interest in Yobee Care, Inc. She is currently employed by Ann & Robert H. Lurie Children's Hospital of Chicago and is a Professor of Pediatrics & Medicine at Northwestern University Feinberg School of Medicine.



Thomas Roades, MPP, is a Policy Research Associate at the Duke-Margolis Institute for Health Policy. He co-leads the Duke-Margolis ReVAMP Drug Supply Chain Consortium, and has worked on drug supply chain, manufacturing, and drug shortage issues throughout his time at Duke-Margolis. His work on Duke-Margolis' Biomedical Innovation portfolio has also included public health and pandemic preparedness and various areas of FDA policy. Prior to joining Duke-Margolis, he received his master's degree in public policy from the University of Virginia.

COI: Thomas declares that he has no conflicts of interest related to this public workshop. He has no personal or financial relationships that could influence his participation.



Tim Dribin, MD, is an Associate Professor of Pediatric Emergency Medicine at Cincinnati Children's Hospital Medical Center. He is a nationally recognized expert in anaphylaxis, and his research program aims to improve care and outcomes for children and adults with anaphylaxis through a multidisciplinary, team science-based approach. Dr. Dribin has led multicenter studies exploring observation periods after epinephrine administration and identifying risk factors for severe allergic reactions. He co-chaired an international expert panel that established a consensus definition and clinical criteria for anaphylaxis and has published extensively in leading journals, including The Journal of Allergy & Clinical Immunology and The Lancet Child & Adolescent Health. Supported by a NIAID K23

Career Development Award, his current research focuses on optimizing community and emergency department management of anaphylaxis and improving access to epinephrine through evidence-based guidelines and innovative digital tools.

COI: Dr. Dribin receives research funding from NIH and Cincinnati Children's Hospital Medical Center.



Valerie J. Parker, MSc, is an Assistant Research Director at Duke-Margolis, where she manages one of the institute's cooperative agreements with the US Food and Drug Administration as well as oversees a core workstream of the institute's Real-World Evidence Collaborative, focused on international regulatory efforts to harmonize real-world data and real-world evidence standards. During her time at Duke-Margolis, Valerie has collaborated and led projects on a range of topics including artificial Intelligence; digital health and data; rare diseases; and pharmacology. In addition to her work with the institute, Valerie has worked with Amgen Inc. as a manager on their Global

Regulatory and R&D team, where she assessed and collated international regulator responses to COVID-19 clinical trial standards and laboratory developed tests. She began her career at Epic Systems Corporation where she worked as an implementation project manager. In this capacity, she was able to

see first-hand health systems in action and how health care data is collected and stored. Valerie holds an MS in Global Health and a BA in Cultural Anthropology from Duke University, and she is an active member of the Duke alumni community.

COI: *Valerie declares that she has no conflicts of interest related to this public workshop. She has no personal or financial relationships that could influence her participation.*